Altimmune(US:ALT) Prnewswire·2025-10-06 12:45Core Viewpoint - Altimmune, Inc. is facing a class action lawsuit due to alleged misleading statements regarding the results of its IMPACT Phase 2b MASH trial for Pemvidutide, which led to a significant drop in its stock price following the announcement of trial results that did not meet statistical significance [1][2]. Group 1: Allegations and Impact - The class action is based on a complaint that claims Altimmune provided inflated expectations prior to the announcement of the trial results on June 26, 2025 [1]. - The trial results showed a failure to achieve statistical significance in the primary endpoint of fibrosis reduction, attributed to a higher-than-expected placebo response [1]. - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of ALT during the specified class period are encouraged to register for the class action by October 6, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].